Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
|ClinicalTrials.gov Identifier: NCT01433237|
Recruitment Status : Completed
First Posted : September 13, 2011
Last Update Posted : May 19, 2016
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.
|Condition or disease||Intervention/treatment|
|Sarcoma||Genetic: RNA analysis Genetic: gene expression analysis Other: laboratory biomarker analysis|
- Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS).
OUTLINE: Archived serum samples are analyzed for miR-206 expression.
PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Observational Model:||Case Control|
|Official Title:||A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||May 2016|
- Serum miR-206 as a biomarker for RMS
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01433237
|Principal Investigator:||Hajime Hosoi, MD||Kyoto Prefectural University of Medicine|